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Quality-adjusted life years (QALYs) combine survival and health-related 
quality of life into a single index enabling judgements about the relative value for 
money of health care interventions.  
Objective
The purpose of this study was to investigate the methods used for 
estimating QALY weights included in submissions by industry for listing on the 
Australian Pharmaceutical Benefits Scheme.
Study design
Retrospective descriptive review of submissions considered by the Pharmaceutical 
Benefits Advisory Committee (PBAC) from 2002 to 2004.
Data sources
The database of submissions considered at PBAC meetings was obtained from the 
Pharmaceutical Evaluation Section of the Australian Government Department of Health 
and Ageing.  Further information on each included submission was obtained in the form of 
the PES commentary (expert report) on the submission.
Review methods
Submissions to the PBAC over 2002-04 presenting QALYs as an outcome 
measure were reviewed to identify the methods used to obtain preference-based QALY 
weights.  Information was analysed according to the approach taken to obtain QALY 
weights (multi-attribute utility instrument (MAUI), health state valuation (HSV) experiment 



































































whom the QALY weights were obtained, the appropriateness of the population for the 
instrument, recommendation made by the PBAC and the main indicated category for use 
of the pharmaceutical.
Results
MAUIs were used in 39% of approaches reporting QALYs; the most frequently 
used MAUI was the EQ-5D.  HSV experiments were used in 36% of the approaches and 
generally drawn from the published literature.  Non-preference based approaches (24%) 
included rating scales, mapping transformations and consensus opinions.  Responses 
from patients were used in 58% of the approaches, followed by healthcare professionals 
and investigators (24% and 9% respectively).  Healthcare professionals and investigators’ 
responses were frequently used in non-preference based approaches.  Submissions for 
Nervous system, Infectious disease and Neoplasms were less likely to have presented 
QALY weights derived from a “more appropriate” approach.  The approaches using “more 
appropriate” populations and techniques were associated with a 56% rejection rate of 
submissions by the PBAC compared with 66% of those using “less appropriate”
approaches.
Conclusions
The variability in the quality of QALY weights is troubling. The PBAC Guidelines 
that applied over the period studied neither encouraged nor discouraged cost-utility 
analyses and provided only brief guidance on how QALY studies should be conducted.  A 
consistent approach to the application of standard methods should be used when the 
QALY is used to inform decisions on resource allocation.  The new guidelines released in 
2006 provide more extensive guidance on derivation of QALY estimates and are more 



































































approach to obtaining QALY weights and ideally, should be routinely used in relevant 




































































The Australian Pharmaceutical Benefits Schedule (PBS) aims to provide reliable 
and affordable access to a wide range of necessary medicines for Australian residents and 
eligible visitors through government subsidies.[1]  For a pharmaceutical or vaccine to be 
listed on the PBS, a sponsor prepares a detailed submission according to guidelines.[2]  
Submissions are considered by the Pharmaceutical Benefits Advisory Committee (PBAC), 
an independent statutory body established to make recommendations to the Minister for 
Health on which pharmaceuticals should be subsidised by the Australian government.  In 
January 1993, Australia became the first country to require an assessment of the costs 
and cost-effectiveness as part of the decision-making process for government subsidies of 
medications.[2]  As such, the PBAC process is one of the most developed in the world. 
The PBAC considers each submission on the basis of safety, efficacy, cost-
effectiveness, and the clinical role of the new pharmaceutical relative to the comparator.[2]  
Sponsors of pharmaceuticals are required to provide details on the pharmaceutical (action, 
indications and restrictions, treatment details, main comparator, clinical management), a 
clinical evaluation of the main indication (including a systematic review of all relevant 
randomised trials), an economic evaluation and the estimated impact on government 
health budgets. The PBAC, with the assistance of its subcommittees, appraises each 
submission and makes recommendation for government funding, defers the submission, 
or rejects the submission. Decisions to recommend are presented to the Minister of 
Health for approving.  Decisions to defer are those where the evidence in the submission 
might be accepted in principle but the price of the medication requires negotiation and/or 



































































consideration at a subsequent meeting; it is expected that the sponsor might present new 
clinical evidence, lower the price and/or undertake major revisions to decision modelling 
(e.g. including providing more relevant cost and/or quality of life data). Although economic 
efficiency is not the sole factor considered in reimbursement decisions, the importance 
placed on this highlights the need for a consistent approach to economic evaluation.
One type of economic evaluation, cost-utility analysis (CUA), uses the Quality-
Adjusted-Life-Year (QALY) as its outcome measure.  The QALY has gained popularity as 
the outcome measure of choice for economic evaluations of health care interventions.  
Underlying the QALY measure is a common assumption that health care resources should 
be allocated in such a way as to maximise any health gains in society as measured by 
additional QALYs.[3]  That is, utilitarianism weights the health gains of each individual 
equally to maximize any increase in the level of health of society.  Therefore, all else being 
equal, for a given budget, programs which provide more additional QALYs should be given 
priority for funding over programs that produce fewer additional QALYs.  Since April 2004, 
QALYs have been required by the National Institute for Health and Clinical Excellence 
(NICE) in the economic evaluation of all health care interventions being appraised.[4, 5]  
However, the United States Food and Drug Administration appears to be avoiding the 
concept of QALYs and has rebadged health-related quality of life (HR-QoL) under a 
banner of Patient-Reported Outcomes (PROs).[6, 7] In its latest guidelines, the PBAC has
described QALYs and their use in submissions;[2] a summary is provided here:
QALYs have three key characteristics: 
1. They combine survival and HR-QoL into a single measure that allows comparability 



































































2. Each health state is assigned a preference-based quality of life weight, or ‘QALY 
weight’.*[9-11]  The QALY weight indicates how much of a life year a person would be 
prepared to sacrifice to improve their quality of life from a given health state to full 
health.  It is measured on a cardinal scale such that a year of life in perfect health has 
a score of one and death has a score of zero.  Scores less than zero, to reflect states 
worse than death, are possible.  
3. QALY weights are derived from individuals in stated preference tasks which are 
designed to reflect the individuals’ trade-offs between quality and quantity of life.[2]  
As such, there is some validity to QALYs representing social trade-offs and social values, 
which are desirable properties in a measure of health outcomes for making decisions 
around the funding of health care interventions.[3]  HR-QoL scores which do not indicate 
strength of preference have less intrinsic validity.
To calculate QALYs is a straightforward process.  The duration a person is in a 
health state is multiplied by the QALY weight for that health state.  People may experience 
many health states throughout life; as such, the products of QALY weights and (expected) 
duration for each health state are summed to give QALYs. The two main approaches to 
obtaining QALY weights to calculate QALYs are:
1. Using a multi-attribute utility instrument (MAUI), and
2. Creating scenarios to elicit QALY weights through health state valuation (HSV) 
experiments. 
MAUIs have three key elements:  A generic quality-of-life instrument, a scaling 
technique (based on a stated preference task, such as a time trade-off (TTO) and standard 



































































make between health outcomes (i.e. preference-based rankings of health states), and a 
mathematical or statistical model that provides a scoring algorithm to generate QALY 
weights for any health state that can be described by the instrument.  The quality of life 
instrument consists of a questionnaire which breaks down a health state into (multiple) 
attributes each of which corresponds with one or more questions and responses in the 
instrument. Responses are scaled and the mathematical model combines these attribute 
scores into an overall instrument score.
MAUIs allow health state experiences to be described by patients using a common 
HR-QoL instrument, in an environment that minimises bias in the reporting of that 
experience; MAUIs also assign “strength of preference” from the general population (i.e. a 
valuation) associated with the health states.  In this way, MAUIs are an appropriate and 
practical method to obtain preference-based valuations for HR-QoL.  MAUIs, along with 
disease-specific measures, can be used in clinical trials to collect information at baseline 
and at various time points during follow-up. 
There are several well known MAUIs available that possess the three key 
elements; the most recent is the SF-6D developed by Brazier et al. to transform SF-36 or 
SF-12 scores into QALY weights.[12, 13] The most widely used is the EQ-5D;[14, 15] others 
include the Health Utilities Index (HUI2 and HUI3)[16, 17] and the Assessment of Quality of 
Life (AQoL).[18, 19] These MAUIs are all based on acceptable scaling techniques using the 
SG or TTO.[8, 20]  The comparative merits of the SG and TTO techniques have been the 
subject of some debate; however, there appears to be no established compelling 
normative or empirical reason to favour the SG over the TTO method or vice versa.[8, 21]



































































acceptance.[2]   Moreover, there is variation between scores derived from MAUIs;[18] this 
variation may be due to the preferences of the population valuing the health state, cultural 
differences and differences in the construction and domains of the instruments.  
An alternative to using a MAUI is the use of HSV experiments.  In HSV, stated 
preference experiments around health state scenarios are undertaken to elicit QALY 
weights.  The scenarios are often hypothetical, and the respondents may be patients or 
drawn from a community sample. The stated preference experiments generally involve an 
explicit trade-off between health profiles described by HR-QoL and survival durations.  The 
TTO and SG have been the most commonly used approaches for HSV experiments.  Such 
experiments generally involve face-to-face interviews requiring numerous decisions by 
participants to identify their preferences.  These can be relatively labour-intensive and 
sometimes cognitively challenging.  Rating scales have been appealing because they are 
easy (and inexpensive) to use, but they do not involve a choice or a trade-off to be made 
between HR-QoL and survival, and therefore, the relative strength of preference cannot be 
inferred validly.
While there continues to be debate about methods for deriving QALYs, there is 
general agreement that QALYs, as a measure of health benefit, should have a sound 
basis in measurement of individuals’ relative preferences for health states such that they 
capture the values of society as a whole.[22-24] Recognising the need for consistency, NICE 
and the U.S. Panel on Cost-Effectiveness in Health and Medicine have produced 
reference cases for undertaking economic evaluation for pharmaceuticals and health care 
interventions.[4, 25]  Both reference cases suggest the use of choice-based techniques to 



































































use of a representative sample of the public as the most appropriate source for 
preferences.  This approach is now also encouraged in the most recent version of the 
PBAC Guidelines (2006).[2]
This descriptive study investigates the methods used for estimating QALY weights 
included in submissions from industry to the PBAC for listing on the PBS prepared 
according to previous versions of the PBAC Guidelines which neither encouraged not 
discouraged cost-utility analysis.  We review the submissions that have reported QALYs 
as a measure of health outcomes with the purpose of identifying the approach taken to 
obtain QALY weights, assessing whether this approach involved use of a MAUI or HSV 
experiments for scaling the health states, and identifying the population from whom the 
QALY weights were obtained.  We do not assess the strengths and weakness each of of 
the various MAUIs or the different HSV techniques to elicit preferences (e.g. we do not 
compare TTO with SG).  In addition, we assess whether the approach used has any 
bearing on the PBAC’s decision to recommend or reject the submission.  Of note is that 
submissions may include both a cost-effectiveness analysis (CEA) and CUA to support 
their case.  Thus, the PBAC may place greater weight on the CEA if the quality of the CUA 




































































The database of submissions considered at PBAC meetings was obtained from the 
Pharmaceutical Evaluation Section (PES) of the Australian Government Department of 
Health and Ageing (DoHA).  All submissions considered by the PBAC at their meetings 
between January 2002 and December 2004 that reported QALYs as an outcome measure 
were included for this analysis.  Further information on each included submission was
obtained in the form of the PES commentary on the submission.  These commentaries are 
prepared by expert analysts who prepare detailed critical reports on each submission.  
Included submissions were sorted according to which of the following approaches 
were used to obtain QALY weights:
1. Use of a MAUI 
2. Use of a HSV experiment in response to health state scenarios
3. Non-preference based approaches. 
We extracted data from the commentaries on the submissions focussing on the 
approach used to obtain QALY weights.  When a MAUI was used, details of the instrument 
and the population completing the questionnaire were recorded.  Where an approach 
involved HSV experiments around health state scenarios, the technique and population 
from whom preferences were elicited were recorded.  Finally, details were noted for non-
preference based approaches, including rating scales and mapping transformations.  We 
have included mapping transformations in this category where the mapping function 
involved mapping a disease-specific or generic HR-QoL scale onto a 0-1 scale that did not 



































































Well-being index [26]).  Likewise, rating scales (e.g. visual analogue scales, VAS) do not 
require a trade-off or choice decision to be made.  As such, scores from these approaches
are not consistent with the QALY approach, which explicitly trades-off quality of life and 
survival.
Populations from whom QALY weights were obtained were categorised into:
1. Target patient group
2. Healthcare professionals 
3. Investigators
4. General population.
The target patient group are living with or being treated for the disease, and 
includes those actively taking the study medication or those in a clinical trial.  Healthcare 
professionals included clinicians, nurses, and allied health professionals; and the general 
population are a random (and potentially representative) sample of society.  
Where the submission relied on data from published literature, the primary study 
was retrieved.  Where more than one of the above approaches to estimate QALY weights 
was used in a submission, the approaches were analysed separately.  For example, if a 
submission used a MAUI and a HSV experiment to derive QALY weights, both were 
recorded and considered independently. Similarly, when an approach was used in more 
than one population group (e.g. a HSV experiment was undertaken by the general 




































































The approach and the population were then classified as “more appropriate” and 
“less appropriate”.  The “more appropriate” approaches were where a MAUI was 
administered to  patients who were currently experiencing the health states being valued,
or when a HSV experiment (such as a TTO or SG) was undertaken in either the general 
population to value a health state derived from clinical and quality of life studies or a 
population of patients to value their own health state.  All other approaches were 
considered “less appropriate”.  We also sorted data into recommend, reject, or defer 
according to the outcome from the PBAC meeting.
Because data submitted to the PBAC was bound by secrecy provisions in the 
National Health Act 1953, it is not possible to name the pharmaceuticals or indications 
requested in the submissions.  However, we do disaggregate results according to a 




































































The PES database contains 230 unique submission numbers which were 
considered by the PBAC at meetings during 2002 to 2004.  A total of 49 (21%) 
submissions were identified that included QALYs (Table I).  These 49 submissions were 
included in this study for further consideration.  There was no apparent trend in the 
proportion of submissions reporting QALYs, with 18%, 27% and 19% in 2002, 2003 and 
2004 respectively.  
The 49 submissions with QALYs consisted of new submissions (27%), 
resubmissions (51%)**, submissions for a change to listing (12%), and other submissions 
such as deferred PBAC considerations and submissions in response to pricing matters 
(10%) (Table I).  
TABLE I ABOUT HERE
Five of the 49 submissions identified had insufficient information available to allow 
analysis of the approaches used to derive QALY weights and were excluded from further 
analysis.  Of the preference source(s) and methodology used in the 44 submissions with 
data available, 11 submissions used more than one approach and two submissions 
presented four approaches.  Overall, there were 66 approaches reported from 44 
submissions.  Of the 66 approaches used in the submissions, 47 (71%) approaches were 
taken from studies previously published in academic journals; the remaining 19 (29%) 
presented studies specifically undertaken for the purposes of preparing a cost-utility 



































































used in the submissions, 16 (24%) resulted in a positive recommendation for the drug, 10 
(15%) were deferred and 40 (61%) were rejected.  
The approaches used
MAUIs and HSV experiments were the most frequently employed approaches 
accounting for 26 (39%) and 24 (36%) of the approaches respectively. Non-preference 
based approaches accounted for 16 (24%) of all approaches used.  When a specific study 
was undertaken for the purposes of a submission, MAUIs were most frequently used 
(12/19; 63%) followed by non-preference approaches (5/19 26%) and two (11%) 
undertook a HSV experiment.  
Of the MAUIs used (n=26), the EQ-5D was the most common (15/26; 58%), 
followed by the AQoL (6/26; 23%), and the relatively new SF-6D (3/26; 12%) (Table II). Of 
the HSV experiments, the TTO was used in 14/24 (58%), SG in 5/24 (21%), and both TTO 
and SG were used in 5/24 (21%) of the approaches.  The five approaches referring to 
combined use of the TTO and SG all referred to one paper in the published literature;[27]
however, the details of how the TTO and SG were implemented and combined was not 
reported in that paper.    
TABLE II ABOUT HERE
Of the non-preference based approaches, mapping functions and rating scales 
were each employed in 7/16 (44%) approaches, with consensus opinion and an 
unvalidated instrument in the remaining 2/16 (12%).  All mapping functions were 



































































published algorithm was used twice[26] and two approaches developed algorithms 
specifically for the submissions.  Use of non-preference approaches, including global 
quality-of-life scores and visual analogue scales, were relatively more common in specific 
studies compared with approaches drawn from the literature (i.e. 8/19 (42%) vs 8/47 (17%) 
respectively).
Submissions employing MAUIs had the lowest rejection rate in PBAC decisions 
(14/26; 54%) whereas 15/24 (62.5%) submissions with HSVs had rejections; non-
preference approaches had the highest rejection rate (11/16; 69%) but surprisingly, 3/16 
(19%) non-preference approaches were associated with positive recommendations (Table 
II). 
The participants
Of the 66 approaches used, six sampled from more than one population group.  
When a MAUI was used, patients with the relevant condition completed the instrument 
based on their current health state in 18/26 (69%) occasions (Table III); 8/26 (31%) were 
completed by proxy (or a combination of patients and proxy) based on an assessment of 
each health state.  These proxies were healthcare professionals or the investigators; in 
6/26 (23%) of occasions, scenarios describing health states had been developed by the 
investigator and the proxy asked to complete the questionnaire.  In another 2/26 (7%) of 
occasions, the investigator or health professional completed the questionnaire based on 
their impression of the patient’s health state.  



































































For those submissions that included a HSV experiment, preferences were elicited 
from patients on 12/24 (50%) occasions and from healthcare professionals on 7/24 (29%) 
occasions.  The general population was used in 2/24 (8%) and were included in a mixed 
sample in a further 2/24 (8%) of occurrences.  Most notable was that there was only one 
specific study which undertook a HSV experiment; all other HSV experiments were 
sourced from published studies. 
In the non-preference based approaches, patients were the most common group 
reporting “QALY weights” (8/16; 50%) followed by investigators (4/16; 25%), healthcare 
professionals (3/16; 19%) and investigators plus healthcare professionals combined (1/16; 
6%).  
Overall, QALY weights derived using “more appropriate” approaches were used in 
the majority of approaches (34/66; 52%).  The remainder used non-preference approaches 
(16/66; 24%) or “less appropriate” populations (16/66; 24%) responding to MAUIs or 
HSVs.  Of the 34 “more appropriate” approaches, 56% were in submissions for drugs 
rejected by the PBAC. Rejection rates were slightly higher for submissions with HSV’s 
(10/16; 63%) compared with MAUIs (9/18; 50%). This may reflect greater potential for 
uncertainty about the methods for HSV approaches. 
The clinical indications
Results were disaggregated into general categories based on the indicated use; 




































































Submissions for drugs to treat Neoplastic disorders tended to use a MAUI but with 
responses from healthcare professionals (Table IV); most of these submissions were 
rejected.  HSVs were frequently used in submissions for Infectious diseases; however, the 
response population was split between healthcare professionals and patients.  MAUIs and 
HSVs were both used in submissions for drugs to treat Mental disorders with responses 
more often from patients (3 HSVs and 3 MAUIs were completed by patients); the PBAC 
made one positive recommendation and one deferred decision (both of these involved 
MAUIs completed by patients) and rejected all other submissions in this category. 
Musculoskeletal system disorders had the greatest number of submissions over the 2002-
04 period; almost half employed a MAUI and a quarter used a non-preference approach to 
QALYs.  In this indication, most submissions used a “more appropriate” approach (14/23; 
61%) of which 10/14 (71%) were in submissions rejected by the PBAC.  
Half of the submissions for drugs to treat Nervous system disorders (3/6; 50%) 
employed MAUIs but 2/3 (67%) used responses from healthcare professionals; positive 
recommendations were made for the HSV with responses from patients and for a non-
preference approach with responses from clinicians.  Other diseases and disorders all 
used responses from patients; 7/10 (70%) of these were “more appropriate” approaches of 
which only 2/7 (29%) were in rejected submissions.  




































































The 21% of submissions to the PBAC using QALYs represents a considerable 
increase over the 2.5% found by George et al. in the early 1990’s.[28]  Given the increased 
support for QALYs as the primary outcome measure, particularly by the NICE,[4] and now 
by the PBAC,[2] it is expected this proportion will continue to rise in the future.  Therefore, 
the comparability and appropriateness of the approaches and methodology used to derive 
QALY weights is an important consideration.
The findings of this study suggest that, in the recent period studied, there was little 
consistency in the approaches and methods used to estimate QALY weights in 
submissions considered by the PBAC.  MAUIs and HSV experiments were most widely 
used, accounting for 39% and 36% of the approaches used respectively.  Surprisingly, 
non-preference based approaches were used in almost 24% of approaches.  The 
submissions considered in this study were prepared using the guidance in the 1995 PBAC 
Guidelines (and 2002 revision), which did not require CUA, and provided limited guidance 
on the derivation of QALYs.[29] Typically, CUA was used as a supplementary analysis to 
augment a base case CEA, which may have reduced the sponsor’s perceived necessity to 
obtain high quality QALY weights as the PBAC may have primarily relied on the CEA as 
the analysis guiding their decision.  The revised PBAC guidelines released in 2006 
provided more detailed guidance on QALY approaches and include a more explicit 



































































Approaches reporting use of a MAUI had the lowest rate of drugs rejected by the 
PBAC (54%) whereas approaches using a HSV or non-preference approach were more 
likely to be in rejected submissions (63% and 69% respectively).  When a submission used 
a “more appropriate” approach, 56% were rejected by the PBAC.  It is emphasised here 
that a “more appropriate” approach does not mean the recommendation will be positive; 
however, a “less appropriate” approach and/or poorly selected population may increase 
uncertainty and be a strong contributing factor to a rejection decision.  The magnitude of 
the cost-utility ratio and the uncertainty are only two factors considered by the PBAC in 
their decision-making process.  Other factors include safety, efficacy, and the clinical role 
of the new pharmaceutical (or vaccine) relative to the comparator.  Moreover, a CUA was 
not required by the PBAC during the study period, and only 21% of submissions included a 
CUA.  In many cases CUA may be used as a supplementary analysis to augment a base 
case cost-effectiveness analysis, and therefore, the PBAC may, when there is uncertainty 
arising from the CUA approach, place greater emphasis on the CEA results.  As such, it is 
possible that obtaining QALY weights or using a “more appropriate” approach was not 
given sufficient priority.   
Of those submissions that did include a CUA, many studies to generate QALY 
weights were of low quality.  For example, proxies such as investigators and healthcare 
professionals are not representative of society; likewise, non-preference based 
approaches cannot reflect society’s preferences or be used to provide QALY weights.  The 
inconsistencies found provide challenges for the decision-making process and increase 
uncertainty.  To some extent, the inconsistencies and inappropriate methods may be 
related to a limited amount of data being available to the sponsors at the time of 



































































trials without regard for the concurrent collection of data necessary for a good economic 
evaluation (i.e. use of a MAUI and resource use data).  Although large multinational trials 
are often run from a centre in the USA or Europe, there is a need to allow and encourage 
the inclusion of local country-specific data in the data collection process. Without local 
data, additional uncertainties are introduced when transferring results to Australia.  Ideally, 
country-specific data on resource use, costs and health outcomes would be available in 
adequately powered multinational trials; this would also allow differences between the 
aggregate and country-specific results to be assessed for generalisability.  In future, it is 
recommended that validated, generic MAUIs (with the relevant country-specific scoring 
algorithm) are routinely included in all relevant comparative randomised trials. 
The most appropriate use of a MAUI for obtaining QALYs involves completion of 
the instrument by blinded participants in a randomised trial to rate their own health at 
baseline and various points during follow-up using the instrument.  This study found that 
no MAUI was used in this way.  Most MAUIs were administered to (non-trial) patients with 
the condition under study, which raises some uncertainty in the validity of the matching of 
their results to the sets of patients taking the therapies being compared in the analysis.  
In some uses of a MAUI, health state scenarios were described for completion of 
the MAUI by a healthcare professional or investigator.  The use of a MAUI to generate 
QALY weights from scenarios is inappropriate.  In an extreme case, the investigator could 
effectively nominate the QALY weight expected based on his or her own opinion and then 
construct scenarios aligned to the text of the MAUI.  That is, it would be near impossible to 
describe a health state to a respondent without actually telling them how to rate it on the 



































































randomised trial, there are numerous advantages of MAUIs including more accurate and 
unbiased measurement of health states, comparability across studies (and internationally), 
and efficiency for respondents and analysts (because no MAUI takes longer than 5-8 
minutes to complete and analysis is well developed).[2]
When a HSV experiment is undertaken, a choice-based technique, such as the SG 
or TTO, should be used to elicit preferences for the described health states.  To avoid the 
introduction of bias and self-interest, preferences should be obtained from a representative 
sample of society.[2]  Preferences elicited from representative samples of society may be 
inconsistent with those of patients who may be elderly, young, from a particular social 
group, and may have their preferences altered by the disease.  However, preferences 
were rarely elicited from the general population with only 2/24 using the general population 
exclusively, and 2/24 using a mix of patients and the general population.  Instead, 
subgroups of patients or healthcare professionals were commonly used for preference 
elicitation.  This reflects difficulty in ensuring that respondents adequately understand the 
health states that they are requested to choose between.  Furthermore, because there are 
less decision points for the analyst in a MAUI compared with HSV and therefore less 
potential for bias and uncertainty to be introduced by the methods, MAUIs are preferred to 
HSV.
Approaches based on mapping from quality of life questionnaires were often 
inappropriate and/or lacking validity, and frequently did not involve choice techniques.  Of 
particular concern were attempts to derive QALY weights based on expert consensus or 
on an assumed linear transformation of a global quality of life or a rating scale to a QALY 



































































to the theory underpinning economic evaluation; as such they cannot be considered 
appropriate for use in QALY calculations.  Best practice would ensure that any 
transformation function would be based on data collected concurrently for both instruments 
in the same population; unless this approach is taken the validity of any transformation is 
severely compromised and increases uncertainty.  In one submission, QALY weights were 
transformed from the EQ-5D to the AQoL.  This was unnecessary and also created greater 
uncertainty as the rationale for doing so was unfounded and a sensitivity analysis using a 
different set of weights would have provided greater elucidation of the effect of changes in 
those weights. 
When more than one approach was used, it was often used to obtain a QALY 
weight for the same health state.  A second approach was either the same technique 
applied to a different population, or a different technique used in the same population.  The 
additional effort needed to use two approaches could be better spent by finding and using 
one technique with a larger relevant population.  The concept of efficiency suggests that 
greater effort should go into obtaining greater accuracy for the main drivers, and less 
robust estimates may be used for those states that have little effect (such as when there is 
a low probability of going into that health state, or the duration in that state is short).  As 
such, we recommend that any post-trial marginal effort in obtaining QALY weights should 
be directed to collecting data from patients using a MAUI or from the general population 
using HSV.  
The 2006 PBAC Guidelines moderates the preference for obtaining QALY weights 
from the general population with an understanding of the information asymmetry relating to 



































































described the key features of the health state(s) actually experienced and (b) how the 
respondent understands the health state from the analyst’s description before then 
proceeding to generate the valuation via SG or TTO.  In the MAUI context, the respondent 
completing the questionnaire actually understands the health state, so the issues are (a) if 
the respondents are not in the randomised trial(s), how well the patients completing the 
MAUI "match" the patients receiving the alternative therapies being compared, (b) how 
well the questionnaire captures the elements which "drive" the health state and (c) how 
well the separate set of respondents in the general population understand each health 
state assigned when completing the SG or TTO to value the health states assigned and 
(d) how well the scoring algorithm aggregates these.  Because of the difficulty of 
minimising investigator bias, there are greater concerns with HSV experiments.  These 
factors also explain the 2006 PBAC Guidelines preference for MAUIs to be completed in 
the relevant double-blind randomised trials.
The limitations of the current study include the assumption that all data entered in 
the PES database are accurate and complete, and that the analysis is based on the PES 
commentaries of submissions.  The database has been independently checked and 
validated against the commentaries as part of this study.  Whilst there were instances 
when insufficient data were available in a commentary to analyse a submission, it is 
considered unlikely that either the database or commentaries would be sufficiently 
inaccurate to alter the findings of this study.  While we may have double-counted some 
approaches in resubmissions where the approach used did not change, we believe this is 
a reasonable approach to take as sponsors have the opportunity to amend their approach 
to estimating QALY weights; in some cases the feedback from the PBAC on the original 



































































limitations, the data provides a reliable trend of the approaches and methodologies used to 
estimate QALY weights in support of submissions.
In a previous review of submissions for inclusion on the PBS (1994 to 1997), Hill 
and colleagues reported finding examples of inappropriate questionnaire design and
inadequate sample size in time trade-off analyses.[30]  Other studies based on published 
CUAs have found extensive variation in the derivation of preferences.[31-33]  The findings of 
the current study suggest there is a general improvement with increased use of generic 
MAUIs and a reduction in the use of rating scales.  For example, in a review of 228 CUAs 
involving 949 health state descriptions published prior to 1997, Bell and colleagues found 
that 20% of health state values were derived through MAUIs.[32]  This compares to the 
current study which found 43% of approaches used a MAUI.  
In contrast to earlier studies, which found the Rosser Index, HUI (and its 
subsequent variants) and QWB to be the most frequently employed instruments,[31, 32] a 
review of 23 CUAs undertaken alongside clinical trials (based on a MAUI questionnaire 
completed by participants in the trial) and published between 1995 and 2002 found that 
the EQ-5D was the most common MAUI employed (70%) followed by the HUI (and its 
variants) (26%).[34]  This is similar to the findings of the current study where the EQ-5D was 
used in 58% of all MAUIs used.  
The EQ-5D is a generic, validated instrument using choice-based methods for 
preference elicitation, originally based on the preferences of a UK population; more 
recently, a scoring algorithm for the USA population has been developed.[15]  There are 



































































For example, for the health state described in the EQ-5D as 11223, the QALY weights are 
0.506 and 0.255 using the USA and UK preferences respectively.  Significant differences 
in QALY weights between UK and Japan from this instrument were evident;[35] however, 
there were no significant differences across six European countries.[36]  These differences 
in preferences across populations create uncertainties around the applicability of the 
QALY weights to populations other than from whom the preferences were drawn.  QALY 
weights for the EQ-5D and the SF-6D with preferences elicited from the Australian 
population are currently being developed.  This will allow greater consistency and 
applicability for calculating QALYs in Australia. 
Because of the above problems (and others), some analysts advocate abandoning 
QALYs and reverting to clinical outcomes (e.g. cases, life-years etc).[37]  However, this 
would reintroduce a lack of outcome comparability across health care programmes and 
pragmatically remove our ability to place a societal value on disparate health outcomes 
inherent with a single preference-based measure.  Moreover, this is equivalent to giving a
QALY weight of 1 to all life years and is likely to be an even less accurate representation 
of health outcomes than from the existing instruments.  The problems need to be 
addressed and methods for eliciting preferences and the use of MAUIs need to be further 
developed and used appropriately.[38]  Factors to consider when choosing an MAUI include 
evidence of its validity, reliability, responsiveness/sensitivity (both between groups of 
individuals and in the same individual at different points in time), and feasibility of use in 
the relevant health condition or population.  
The source of the preferences used should also be applicable to the society in 



































































society continue to be uncommonly elicited. We estimate responses were obtained from 
an appropriate population in 52% of QALY approaches submitted to the PBAC (i.e. where 
patients responded to a MAUI or the general population or patients responded to a HSV 
experiment); this is an improvement on the 24% reported by Bell and colleagues and the 
22% reported by Stein from a review of NICE assessments.[32, 33]  
CONCLUSIONS
The quality of QALY weights is troubling and the methodological issues described 
impact on the measurement of health outcomes. A consistent approach to the application 
of standard methods should be used when the QALY is used to inform decisions on 
resource allocation.  The new guidelines released in 2006 provide more extensive 
guidance on derivation of QALY estimates and are more encouraging of the presentation 
of cost-utility analysis.  MAUIs offer a straightforward approach to obtaining QALY weights 





































































* We use the term “QALY weight” to distinguish the weights used to estimate 
QALYs from the scoring systems commonly used in quality of life instruments, such as the 
SF-36. The scores for the latter are not based on any direct measurement of individual 
preferences, and hence there is no indication of strength of preference for different health 
states, or for the trade-offs individuals may make between dimensions of HR-QoL that 
contribute to the instrument. Elsewhere QALY weights are sometimes referred to as 
utilities or utility weights, and claimed to have a basis in Von Neumann Morgenstern 
expected utility. However, QALYs are only a measure of utility if additional strong 
restrictions are imposed on the utility function.[9-11]
** A resubmission is a submission that was previously rejected by the PBAC; the 
sponsor may choose to resubmit to provide additional information and/or make other 
appropriate amendments. The main reasons for rejections typically include insufficient 
evidence on the clinical benefit (e.g. from a different target population to that described in 
the evidence provided), too much residual uncertainty around the clinical benefit or cost-
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